Download the Protocol

hCG

hCG is a natural hormone that signals the body to produce reproductive hormones. It is best known for supporting pregnancy but is also used in research and medicine to stimulate testosterone production and ovulation. It acts similarly to luteinizing hormone (LH) to trigger the release of sex hormones in both men and women.

Description

• hCG is a glycoprotein hormone naturally produced by the placenta during pregnancy.
• Binds to LH/hCG receptors, promoting luteal support and gonadal steroid production.
• Used in clinical and research settings to induce ovulation or stimulate testosterone production.

How It Works

• Activates LH/hCG receptors in the ovaries and testes to initiate steroidogenesis.
• In males, stimulates Leydig cells to produce testosterone and support spermatogenesis.
• In females, maintains progesterone production by sustaining the corpus luteum during early pregnancy.

Documented Effects

• Induces ovulation in fertility treatment protocols.
• Stimulates endogenous testosterone and sperm production in male hypogonadism.
• Supports luteal function during assisted reproduction protocols.

Theoretical Effects

• Potential applications in fertility recovery and hormone axis restoration studies.
• Investigated for use in testicular atrophy prevention during anabolic suppression models.
• Not supported for fat loss or metabolic enhancement in scientific literature.

Pharmacokinetics

• Half-life: 24–36 hours after subcutaneous or intramuscular injection.
• Time to peak effect: within 6–12 hours post-injection.
• Duration of effect: up to 48–72 hours depending on dose and route.

Duration of Effects

• Hormonal activity can persist for several days due to receptor affinity.
• Repeated injections sustain LH-mimetic activity and hormonal output.
• Overuse may blunt response due to receptor desensitization.

Reconstitution

• Use only bacteriostatic water to reconstitute lyophilized hCG powder.
• Example vial: 5,000 IU (≈5 mg)
• Choose reconstitution volume based on dosing convenience:
  • 1 mL → 5,000 IU/mL → 500 IU per 0.1 mL (10 units)
  • 2 mL → 2,500 IU/mL → 250 IU per 0.1 mL (10 units)
• Swirl gently to dissolve; avoid shaking.
• Refrigerate reconstituted solution (2–8 °C). Use within ~14 days for best stability.

Injectable Dosage Overview (Research / Clinical Reference)

Typical Starting Dose

• Male research use: 500–1,000 IU subcutaneous (SC) every 2–3 days.
• Female ovulation protocols: 5,000–10,000 IU intramuscular (IM) single injection.

Common Research Range

• 500–2,000 IU SC every 2–3 days for hormonal stimulation or fertility models.
• Monitored for testosterone, LH, and FSH regulation effects.

Maximum Research Range

• Up to 10,000 IU single injection for ovulation induction under medical supervision.
• Excessive or continuous use can lead to receptor desensitization and hormonal imbalance.

Standard Cycle Length

• Short cycles: 2–4 weeks for hormone stimulation or recovery research.
• Extended use (6–8 weeks) may be used in combination with other hormonal agents under strict supervision.

Combination Research

• Often paired with GnRH analogs (e.g., Gonadorelin) or FSH peptides to replicate full reproductive axis stimulation.
• Can be used to maintain testicular function during anabolic suppression in lab studies.

Clinical Notes

• Administer subcutaneously in the lower abdomen or intramuscularly; rotate injection sites to reduce irritation.
• Used to support testosterone production by stimulating Leydig cells; also maintains testicular volume during TRT.
• Best dosed in smaller, more frequent pulses (e.g., 2–3× weekly) to mimic natural LH signaling.
• May increase estradiol via aromatization; monitor symptoms such as nipple sensitivity or water retention.
• Can transiently increase mood, libido, and energy due to acute androgen and neurosteroid changes.
• Stable for about 14 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes

• Possible effects: mild water retention, mood changes, acne, or local injection irritation.
• In women: risk of ovarian hyperstimulation syndrome (OHSS) when combined with fertility drugs.
• In men: chronic overuse may suppress endogenous LH and reduce testicular sensitivity.
• Use sterile preparation and storage; not intended for unsupervised human use.